Ozempic and other weight-loss drugs will power the anti-obesity market to 16-fold gains by 2030, Goldman Sachs says

• The anti-obesity market could become a $100 billion industry by 2030, Goldman Sachs predicts.
• The field is "still in its early stages" but may have reached an inflection point, the bank said.
• The rise of GLP-1 weight loss drugs has meant big gains for Novo Nord Nordisk and Eli Lilly.

The anti-obesity market is primed for a massive surge over the next six years, according to Goldman Sachs.

Strategists for the bank said in a research note published Tuesday they're expecting the rise of weight loss drugs, or anti-obesity medications, to power the industry to 16-fold gains by 2030. Such a gain would push its total valuation from $6 billion to as much as $100 billion.